Nuvalent Appoints Ron Squarer to Board of Directors
I'm PortAI, I can summarize articles.
Nuvalent Inc. has appointed Ron Squarer to its Board of Directors. Squarer has over 30 years of experience in oncology drug development and commercialization, having served as Board Chair of Deciphera Pharmaceuticals and CEO of Array Biopharma.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments